Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04101045 · ClinicalTrials.gov registry record · NA

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

A NA study, sponsored by Yale University.

Terminated
Registry status
NA
Development phase
7
Enrollment target

NCT04101045 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04101045, a NA study, was terminated before completion, sponsored by Yale University.

TERMINATED
Registry status
NA
Development phase
7 participants
Enrollment target

Study Summary

The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control (HbA1c \<7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fractional hepatic DNL during the fasting and the postprandial states than youth who achieve targeted glycemic control and lean controls.

Interventions

  • DIAGNOSTIC_TEST Oral Glucose Tolerance Test

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-11-21
Est. Completion 2022-03-30
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04101045

The ClinicalTrials.gov registry entry for NCT04101045 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Oral Glucose Tolerance Test is the first listed.

NCT04101045 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04101045 about?

NCT04101045 is a clinical study titled "Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes". The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control (HbA1c \<7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fra...

What is the current status of trial NCT04101045?

This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2019-11-21. Estimated completion is 2022-03-30.

What interventions are being tested in trial NCT04101045?

The interventions under investigation include: Oral Glucose Tolerance Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04101045?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.